Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FH-006 + adebrelimab + BP102
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FH-006 + SHR-1316 + BP102 is an investigational combination regimen developed by Jiangsu HengRui Medicine for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). The regimen consists of FH-006, a novel investigational agent; SHR-1316 (adebrelimab), a humanized IgG4 monoclonal antibody targeting programmed death-ligand 1 (PD-L1); and BP102, a bevacizumab biosimilar targeting vascular endothelial growth factor (VEGF). This triplet combination is designed to enhance anti-tumor activity by simultaneously restoring T-cell mediated immune responses and inhibiting tumor-induced angiogenesis. It is currently being evaluated in a Phase II clinical trial (NCT07241767) to assess its safety, tolerability, and efficacy, both as a standalone triplet and in combination with platinum-based chemotherapy (cisplatin or carboplatin) in patients with advanced lung cancer.
- Other names
- FH-006 + adebrelimab + bevacizumab biosimilar
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)CD80 (T-lymphocyte activation antigen CD80)
Beyond the preview
Go deeper on FH-006 + adebrelimab + BP102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FH-006 + adebrelimab + BP102.